



## Investor Webinar

2 March 2022 [ASX:RHY](#)

*A transformative and predictive  
cancer diagnostics technology company*

[rhythmbio.com](http://rhythmbio.com)

# Disclaimer



This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

# Introduction



Rhythm's initial product, ColoSTAT<sup>®</sup> is a **simple, low-cost** blood test for the early detection of colorectal cancer for **global mass-market** screening.

IP protection **secured** in all major international jurisdictions.



# Agenda



- ✓ Overview of commercialisation progress for ColoSTAT<sup>®</sup> - a simple, low-cost, blood test for global mass market detection of colorectal cancer;
- ✓ Rhythm's platform technology expansion strategy into other cancer targets;
- ✓ Future catalysts and news flow for the current calendar year; and
- ✓ A question & answer session.


# Company Overview



## Capital Structure

ASX Code	<b>RHY</b>
<b>Share Price</b> (at 1 March 2022)	<b>\$1.18</b>
Shares on Issue	214.1 M
Unlisted Options	16.8 M
<b>Market Capitalisation</b>	<b>\$251.6 M</b>
Cash in bank (28 February 2022)	\$10.8M
Top 20 Shareholders	46%

## Share Price Chart




## Board and Management

Otto Buttula	Glenn Gilbert	Trevor Lockett	Lou Panaccio	Eduardo Vom	Rachel David
Chairman	CEO & Managing Director	Executive-Director	Non-Executive Director	Non-Executive Director	Non-Executive Director
<ul style="list-style-type: none"> <li>Extensive financial, investment and biotech experience.</li> <li>Co-Founder and CEO of IWL (ASX: IWL); Founder / former CEO of Investors Mutual.</li> <li>Formerly a Director of Imugene (ASX: IMU) and Chairman of Investorfirst, now HUB (ASX: HUB).</li> <li>Chairman of HITIQ (ASX: HIQ), Non-Executive Director of Oncosil Medical (ASX: OSL).</li> </ul>	<ul style="list-style-type: none"> <li>Former Head of Global Sales, Marketing and BD at Medical Developments Int. (ASX: MVP).</li> <li>Various leadership positions at CSL (ASX: CSL).</li> <li>Strong Legal, IP &amp; Operational management.</li> <li>Broad international business experience.</li> </ul>	<ul style="list-style-type: none"> <li>Former Theme Leader Colorectal Cancer and Gut Health CSIRO.</li> <li>Leader – Personalised Health Group CSIRO.</li> <li>Inventor on seven commercially-licensed patent families.</li> </ul>	<ul style="list-style-type: none"> <li>Chairman Avita Medical (ASX: AVH).</li> <li>Director Sonic Healthcare (ASX: SHL).</li> <li>Chairman NeuralDX.</li> <li>Non-executive Director, Adherium (ASX: ADR).</li> <li>Non-executive Director Unison Housing.</li> <li>Former CEO Melb Pathology &amp; Monash IVF.</li> </ul>	<ul style="list-style-type: none"> <li>Co-Founder &amp; Executive Director Planet Innovation.</li> <li>Director Atmo Biosciences.</li> <li>Former VP Innovation, Genetic Technologies.</li> <li>Various senior leadership positions Vision BioSystems.</li> </ul>	<ul style="list-style-type: none"> <li>Currently the Chief Executive Officer (CEO) of Private Healthcare Australia (PHA).</li> <li>Senior Director Government Affairs, Policy and Market Access for Johnson &amp; Johnson.</li> <li>Various senior roles with McKinsey, CSL and Pfizer (formally Wyeth).</li> </ul>

# Market Opportunity / Addressable Market



US\$38 billion addressable screening value in priority markets<sup>1</sup>



## Colorectal Cancer Screening Market Population

Number of people over 50 years of age eligible for screening

Country	Screening participation	Addressable population
United States	63%	94 million
Europe	38%	231 million
China	19%	397 million
Japan	38%	42 million
Australia	41%	7 million
<b>Total</b>		<b>771 million people</b>


**Potential to reach ~1 billion people**  
when the screening age is lowered to 45 years old

<sup>1</sup> Based on 2021 data calculated as Eligible Screening Population (771 million) x Example Test Cost (US\$50). RHY revenue may vary.

# ColoSTAT<sup>®</sup> Performance



“83% of unscreened participants prefer a blood test over a faecal test”<sup>1</sup>



- **Highly accurate**  
ColoSTAT is 33% more accurate at detecting colorectal cancer than the current market standard Faecal Immunochemical Test (FIT).<sup>2</sup>
- **Low Cost and Simple**  
Protein biomarker led delivers a cost-efficient simple blood test that is suited to global mass market screening programs.
- **Detects Cancer**  
Disruptive technology that detects the presence of cancer in the blood whereas current FIT based testing regimes only detects the presence of blood in a stool sample.
- **Preferred**  
A blood test is preferred as a more acceptable way to participate in testing.

<sup>1</sup> 9. Osborne, J., Wilson, C., Moore, V., Gregory, T., Flight, I. and Young, G. (2012) Sample preference for colorectal cancer screening tests: Blood or stool?. Open Journal of Preventive Medicine, 2, 326-331. doi: 10.4236/ojpm.2012.23047.

<sup>2</sup> Symonds EL, Pedersen SK, Baker RT, Murray DH, Gaur S, Cole SR, Gopalsamy G, Mangira D, LaPointe LC, Young GP. A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia. Clinical and Translational Gastroenterology (2016) 7, e137; doi:10.1038/ctg.2015.67.

# Clinical Trial (Study 7) – Performance In A Clinical Setting



## PRIMARY ENDPOINT:

- Performance of ColoSTAT<sup>®</sup> for detection of CRC relative to colonoscopy (**Sensitivity and Specificity**).

### Key Steps (not exhaustive list):

- ✓ Complete patient recruitment. **Done.**
- ✓ Database locked at trial sites. **Done.**
- ✓ Testing of blood samples at Sonic Clinical Trials. **Done.**
- Statistical analysis of results. **Underway.**
- Close clinical trial sites. **Underway.**
- Final clinical study report completion. **Underway.**
- Collation of data and study results / report in ColoSTAT<sup>®</sup> technical file. **Underway.**
- Submit technical file and other associated documentation to Therapeutic Goods Administration (TGA). **On track for 1HCY'22.**

### ColoSTAT<sup>®</sup> Clinical Trial to confirm:

- ✓ Performance translates to a clinical setting;
- ✓ Anticipated performance to successfully meet key primary endpoint.
- ✓ Supports TGA regulatory submission.

### TGA submission process requires two key filings:

- Manufacturers Evidence documentation. **Submitted and accepted**; and
- Application for an Australian Register of Therapeutic Goods (ARTG) listing. **Underway.**



# Platform Technology Expansion



- The expansion program is expected to be significantly shortened, leveraging the Company's lead biomarker which exhibits **pan-cancerous** properties;
- A platform expansion program identified a number of additional cancer target markets that will form part of a new Research and Development program designed to follow a similar commercial pathway to ColoSTAT®;
- The initial five additional cancers to be targeted include:
  - ✓ Breast;
  - ✓ Cervical;
  - ✓ Lung;
  - ✓ Gastric; and
  - ✓ Pancreatic.
- Expedited program commenced, significant upside potential.

# Appointment of General Counsel & Co Sec



- ✓ Ms Andrea Steele has been appointed as General Counsel and Company Secretary;
  - Ms Steele has a Bachelor of Laws (LLB), a Master of Laws (LLM), a Master of Legal Practice and a Bachelor of Commerce (Accounting / Finance);
  - Career spanning over 23 years and includes management consultancy positions throughout Europe and Australia, Corporate Strategy Analyst at IWL Limited (ASX: IWL) and Corporate Strategy and Company Secretary at Investorfirst Ltd (now ASX: HUB). More recently, Ms Steele's roles include General Counsel and EGM – Retail & Regulatory Affairs at WINconnect Pty Ltd.
  - Currently Ms Steele is a Principal Consultant at ENRG Consulting.
- ✓ The Company is entering a transition stage toward further regulatory approvals and commercialisation (including partnering agreements); and
- ✓ The requirement for additional, complementary skill sets has been identified in line with the evolution of the business.

# CY'22 Catalysts



- ✓ Clinical Trial (Study 7) results and clinical study report completion;
- ✓ Technical file complete for ARTG listing for TGA submission and approval;
- ✓ Identify and progress partnering / commercialisation deals (Domestic and International);
- ✓ International country submissions / registration updates;
- ✓ Advance platform technology expansion program (progress updates); and
- ✓ Target first revenues late CY'22.



**Glenn Gilbert**  
**CEO and Managing Director, Rhythm Biosciences**  
**glenn.gilbert@rhythmbio.com**  
**+61 3 8256 2880**

[www.rhythmbio.com](http://www.rhythmbio.com)

